Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study

Phenylketonuria Clinical Trial

Official title:

Neuropsychological and Quality of Life Outcomes in Untreated Adults With Mild Hyperphenylalaninemia (MHP)/Phenylketonuria (PKU) With Phenylalanine Levels Between 360 and 600 µmol/L Caused by Phenylalanine Hydroxylase (PAH) Deficiency.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01924026
• Other study ID #: 1000039726
• Status: Completed
• Phase: N/A
• First received: May 15, 2013
• Last updated: February 13, 2016
• Start date: September 2013
• Est. completion date: February 2016

Study information

• Verified date: February 2016
• Source: The Hospital for Sick Children
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Observational

Clinical Trial Summary

Phenylketonuria (PKU) is a genetic disorder known to cause severe reduction in intelligence and deficits in cognitive function; it is associated with an elevated level of Phenylalanine (Phe) in blood.

Newborn screening and early treatment with restricted protein diet supplemented by a formula of amino-acids will preserve intelligence. In those with the severe form treated from birth, some deficits that affect higher functions of the brain are seen.

Given this, there is disagreement about how milder forms of this disease should be managed and what level of Phe is safe to be left untreated.

We seek to assess whether higher Phe levels, between 360 and 600µmol/L, are safe with respect to preservation of intelligence and higher cognitive functions.

Description:

The following personal/medical information will be collected and reviewed:

• Evaluation of current and past medical history, including psychological treatment such as medication and counseling/therapy.

• Mutational analysis for each MHP subject

• Detailed history of educational, employment, relationship, and socioeconomic status/achievements as a measure of successful transition to adulthood

• Diet history, including past treatment with medical food or Sapropterin (Kuvan) for pre-conceptual and pregnancy Phe management

• All available untreated Phe levels, including newborn screening results (where possible) will be collated to calculate lifetime mean Phe level. Age at collections will be recorded separately for each MHP subjects to ensure inclusion of Phe levels beyond infancy

The following clinical investigations will be administered:

• Measurement of Phe and Tyrosine after an overnight fast, via blood spot using tandem mass spectrometry analysis. Blood spot collection will be done at the same time of day for all subjects.

• Physical exam, height and weight measurements

• Food Frequency Questionnaire assessment to estimate typical daily intake of natural protein.

• Self-Report Questionnaires:

• Behavior Rating Inventory of Executive Function (BRIEF)-A

• Beck Anxiety Inventory

• Beck Depression Inventory

• Quality of Life questionnaire

• Neuropsychological Tests assessed by a trained psychologist

An informant BRIEF-A report will be completed for each subject. To ensure consistency in rating, the same informant will be used where possible for the MHP subject and their sibling control (i.e. parents). These questionnaires will be mailed to the informants and returned to the study site via FedEx.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or Female, = 18 years

• Confirmed to have MHP with at least two Phe levels during lifetime of above 360µmol/L and below 600µmol/L, including newborn screening levels (available since 1968 by either bacterial inhibition, enzymatic or tandem mass spectrometry methodology) and via mutation analysis. Those with occasional levels above 600µmol/L will not be excluded provided the majority of available levels fall within the 360-600µmol/L range.

• On an unrestricted diet and not taking medical food. Women who were on dietary or Kuvan® treatment for past pre-conception or pregnancy management will not be excluded

• Willing and able to give consent and comply with study procedures.

Exclusion Criteria:

• Subjects on dietary or Kuvan® treatment within the last 12 weeks will be excluded.

• Co-morbidities that may interfere with study participation and/or put the subject at a higher risk of adverse effects.

Subjects who do not have an unaffected sibling may still participate.

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Mild Hyperphenylalaninemia
• Phenylketonuria
• Phenylketonurias

Locations

Country	Name	City	State
Canada	The Hospital for Sick Children	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
The Hospital for Sick Children	BioMarin Pharmaceutical

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	IQ	As measured by Wechsler-IV	Day 1	No
Primary	Executive function	As measured by subtests in Weschler-IV test, and supplemented with assessments from BRIEF-A and CANTAB(computerised cognitive tests by Cambridge Cognition).	Day 1	No
Secondary	Quality of Life		Day 1	No
Secondary	Presence of anxiety and depression	As measured by Beck Anxiety and Depression Inventories	Day 1	Yes